T.Naga Ravikiran1*, A.V.S.Madhulatha2, Y.Rajendra Prasad1
1Dept of Pharmaceutical chemistry, AU college of Pharmaceutical sciences,Visakhapatnam. Andhra Pradesh, INDIA.
2Krishna University college of Pharmaceutical sciences, Machilipatnam, Andhra Pradesh, INDIA.
Ebola virus disease (EVD), formerly known as Ebola haemorrhagic fever), is a severe, often fatal illness, with a case fatality rate of up to 90%. There are no licensed specific treatments or vaccine available for use in people or animals. Genus Ebolavirus is 1 of 3 members of the Filoviridae family (filovirus), along with genus Marburgvirus and genus Cuevavirus. Genus Ebolavirus comprises 5 distinct species: Bundibugyo ebolavirus (BDBV), Zaire ebolavirus (EBOV), Reston ebolavirus (RESTV), Sudan ebolavirus (SUDV) and Taï Forest ebolavirus (TAFV). The incubation period of Ebola virus disease (EVD) varies from 2 to 21 days, with an observed average of 8 to 10 days. The most common symptoms experienced by persons infected with the virus are the sudden onset of fever, intense weakness, muscle pain, headache and sore throat followed by vomiting, diarrhea, rash, impaired kidney and liver function, and at advanced stage, both internal and external bleeding. Laboratory findings include low white blood cells and platelet counts and elevated liver enzymes. Currently, no specific licensed therapy has demonstrated efficacy in the treatment of EVD.Nevertheless,a ray of hope blooms in the aisle of exploration in the form of three drugs BCX 4430, Favipiravir, Brincidofovir. PREVENTION IS MANIFOLD BETTER THAN CURE. Withstanding and combating of mankind to this epidemic is dependent on purely the preventive steps adapted and implemented stringently.